레지오넬라균 검사 시장 보고서 : 용도별, 최종 사용자별, 지역별(2025-2033년)

The global legionella testing market size reached USD 366.5 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 658.2 Million by 2033, exhibiting a growth rate (CAGR) of 6.66% during 2025-2033. The increasing number of individuals who have diabetes, kidney disease, human immunodeficiency virus (HIV), cancer, or other chronic illnesses, are at risk of hospitalization, which is stimulating the market growth.

Legionella is an infection affecting the lower respiratory tract, which can lead to severe pneumonia, Pontiac fever, and illness with flu-like symptoms. Its testing helps to identify the existence of bacteria or antigens in blood, urine, and sputum. Presently, various testing methods are available to diagnose Legionella disease, including urinary antigen, paired serology, Polymerase Chain Reaction (PCR), Direct Fluorescent Antibody (DFA) stain, and culture of lower respiratory secretions. As per the testing results, macrolides, quinolones, tetracycline, doxycycline, minocycline, trimethoprim and other antibiotic treatments are usually administered to patients.

Global Legionella Testing Market Trends:

Adults over the age of 50 years are more likely to develop Legionella. Consequently, the increasing geriatric population worldwide represents one of the major factors influencing the market positively. Moreover, the rising number of individuals who smoke and have cancer, diabetes, kidney disease, human immunodeficiency virus (HIV), or other chronic illnesses are at the risk of infection and hospitalization. Since the mortality rate of Legionella is high, there is an increase in the demand for its effective diagnostic tests and treatments. Besides this, Legionella-causing bacteria are majorly found in different natural and artificial aquatic environments, such as cooling towers, respiratory therapy equipment, fountains, misting devices, spa pools, and water systems in hotels, homes, and factories. As a result, health agencies of numerous countries are developing an effective water safety plan (WSP) to minimize the proliferation of Legionella in the water. This, in turn, is escalating the demand for Legionella testing in workplace buildings to comply with the legislation. Furthermore, recent clinical trials on diagnostic and treatment strategies for adult patients with community-acquired pneumonia are contributing to the growth of the market.

Legionella Testing Market Segmentation:

Breakup by Application:

Water Testing

Microbial Culture

DFA Stain

PCR

Others

IVD Testing

Blood Culture

Urine Antigen Test

DFA Stain

PCR

Others

Breakup by End User:

Diagnostic Laboratories

Hospital and Clinics

Others

Breakup by Region:

Europe

Italy

Germany

France

Spain

United Kingdom

Russia

Others

North America

United States

Canada

Asia Pacific

China

Japan

Australia

South Korea

Indonesia

Singapore

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined with some of the key players being Abbott Laboratories, Becton, Dickinson and Company, BioMerieux SA, Bio-Rad Laboratories Inc, Eiken Chemical Co. Ltd, Quidel Corporation, Takara Bio Inc., and Thermo Fisher Scientific Inc.

Key Questions Answered in This Report

• 1. What was the size of the global legionella testing market in 2024?
• 2. What is the expected growth rate of the global legionella testing market during 2025-2033?
• 3. What are the key factors driving the global legionella testing market?
• 4. What has been the impact of COVID-19 on the global legionella testing market?
• 5. What is the breakup of the global legionella testing market based on the application?
• 6. What is the breakup of the global legionella testing market based on the end user?
• 7. What are the key regions in the global legionella testing market?
• 8. Who are the key players/companies in the global legionella testing market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Legionella Testing Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Application

• 6.1 Water Testing
  • 6.1.1 Market Trends
  • 6.1.2 Market Breakup by Type
    • 6.1.2.1 Microbial Culture
    • 6.1.2.2 DFA Stain
    • 6.1.2.3 PCR
    • 6.1.2.4 Others
  • 6.1.3 Market Forecast
• 6.2 IVD Testing
  • 6.2.1 Market Trends
  • 6.2.2 Market Breakup by Type
    • 6.2.2.1 Blood Culture
    • 6.2.2.2 Urine Antigen Test
    • 6.2.2.3 DFA Stain
    • 6.2.2.4 PCR
    • 6.2.2.5 Others
  • 6.2.3 Market Forecast

7 Market Breakup by End User

• 7.1 Diagnostic Laboratories
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Hospital and Clinics
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Others
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast

8 Market Breakup by Region

• 8.1 Europe
  • 8.1.1 Italy
    • 8.1.1.1 Market Trends
    • 8.1.1.2 Market Forecast
  • 8.1.2 Germany
    • 8.1.2.1 Market Trends
    • 8.1.2.2 Market Forecast
  • 8.1.3 France
    • 8.1.3.1 Market Trends
    • 8.1.3.2 Market Forecast
  • 8.1.4 Spain
    • 8.1.4.1 Market Trends
    • 8.1.4.2 Market Forecast
  • 8.1.5 United Kingdom
    • 8.1.5.1 Market Trends
    • 8.1.5.2 Market Forecast
  • 8.1.6 Russia
    • 8.1.6.1 Market Trends
    • 8.1.6.2 Market Forecast
  • 8.1.7 Others
    • 8.1.7.1 Market Trends
    • 8.1.7.2 Market Forecast
• 8.2 North America
  • 8.2.1 United States
    • 8.2.1.1 Market Trends
    • 8.2.1.2 Market Forecast
  • 8.2.2 Canada
    • 8.2.2.1 Market Trends
    • 8.2.2.2 Market Forecast
• 8.3 Asia Pacific
  • 8.3.1 China
    • 8.3.1.1 Market Trends
    • 8.3.1.2 Market Forecast
  • 8.3.2 Japan
    • 8.3.2.1 Market Trends
    • 8.3.2.2 Market Forecast
  • 8.3.3 Australia
    • 8.3.3.1 Market Trends
    • 8.3.3.2 Market Forecast
  • 8.3.4 South Korea
    • 8.3.4.1 Market Trends
    • 8.3.4.2 Market Forecast
  • 8.3.5 Indonesia
    • 8.3.5.1 Market Trends
    • 8.3.5.2 Market Forecast
  • 8.3.6 Singapore
    • 8.3.6.1 Market Trends
    • 8.3.6.2 Market Forecast
  • 8.3.7 Others
    • 8.3.7.1 Market Trends
    • 8.3.7.2 Market Forecast
• 8.4 Latin America
  • 8.4.1 Brazil
    • 8.4.1.1 Market Trends
    • 8.4.1.2 Market Forecast
  • 8.4.2 Mexico
    • 8.4.2.1 Market Trends
    • 8.4.2.2 Market Forecast
  • 8.4.3 Others
    • 8.4.3.1 Market Trends
    • 8.4.3.2 Market Forecast
• 8.5 Middle East and Africa
  • 8.5.1 Market Trends
  • 8.5.2 Market Breakup by Country
  • 8.5.3 Market Forecast

9 SWOT Analysis

• 9.1 Overview
• 9.2 Strengths
• 9.3 Weakness
• 9.4 Opportunities
• 9.5 Threats

10 Value Chain Analysis

11 Porter's Five Forces Analysis

• 11.1 Overview
• 11.2 Bargaining Power of Buyers
• 11.3 Bargaining Power of Suppliers
• 11.4 Degree of Competition
• 11.5 Threat of New Entrants
• 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

• 13.1 Market Structure
• 13.2 Key Players
• 13.3 Profiles of Key Players
  • 13.3.1 Abbott Laboratories
    • 13.3.1.1 Company Overview
    • 13.3.1.2 Product Portfolio
    • 13.3.1.3 Financials
    • 13.3.1.4 SWOT Analysis
  • 13.3.2 Becton, Dickinson and Company
    • 13.3.2.1 Company Overview
    • 13.3.2.2 Product Portfolio
    • 13.3.2.3 Financials
    • 13.3.2.4 SWOT Analysis
  • 13.3.3 BioMerieux SA
    • 13.3.3.1 Company Overview
    • 13.3.3.2 Product Portfolio
    • 13.3.3.3 Financials
    • 13.3.3.4 SWOT Analysis
  • 13.3.4 Bio-Rad Laboratories Inc
    • 13.3.4.1 Company Overview
    • 13.3.4.2 Product Portfolio
    • 13.3.4.3 Financials
    • 13.3.4.4 SWOT Analysis
  • 13.3.5 Eiken Chemical Co. Ltd
    • 13.3.5.1 Company Overview
    • 13.3.5.2 Product Portfolio
    • 13.3.5.3 Financials
  • 13.3.6 Quidel Corporation
    • 13.3.6.1 Company Overview
    • 13.3.6.2 Product Portfolio
    • 13.3.6.3 Financials
    • 13.3.6.4 SWOT Analysis
  • 13.3.7 Takara Bio Inc.
    • 13.3.7.1 Company Overview
    • 13.3.7.2 Product Portfolio
    • 13.3.7.3 inancials
  • 13.3.8 Thermo Fisher Scientific Inc.
    • 13.3.8.1 Company Overview
    • 13.3.8.2 Product Portfolio
    • 13.3.8.3 Financials
    • 13.3.8.4 SWOT Analysis